Drug intelligence / Profile preview

Bristol Myers Squibb ROCK2 compound 22

Development stage: Unknown
Lead developer: Bristol Myers Squibb

Overview

Bristol Myers Squibb ROCK2 compound 22: sourced facts only. name: "Potent ROCK2 inhibitors such as 22 were identified with excellent overall kinase selectivity as well as good isoform selectivity over ROCK1." [PMID:37119973]; target: "Potent ROCK2 inhibitors such as 22 were identified with excellent overall kinase selectivity as well as good isoform selectivity over ROCK1." [PMID:37119973]; developer: "Research & Early Development, Bristol Myers Squibb, P.O. Box 5400, Princeton, NJ 08543-5400, USA. Electronic address: [email protected]." [PMID:37119973]

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)

Beyond the preview

Go deeper on Bristol Myers Squibb ROCK2 compound 22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bristol Myers Squibb ROCK2 compound 22.